Medicare’s GLP-1 Program Looms; Chemicals in Breast Milk; Acromegaly Drug Rejected

Medicare’s GLP-1 Program

A massive wave of new prescriptions for GLP-1 receptor agonists is expected following the July launch of a Medicare pilot program that offers the drugs for weight loss for a flat $50 monthly copay. (Axios)

Meanwhile, nearly 80% of employers said GLP-1 medications are driving an increase in their healthcare costs, and some may drop coverage next year, a Business Group on Health survey found.

The American College of Physicians issued a new clinical guideline on using medications to manage overweight and obesity in adults. (Annals of Internal Medicine)

Data from Chile suggest aggressive food labeling and advertising policies can cut obesity risks in children. (The Lancet)

European Diabetes Association Statement

The European Association for the Study of Diabetes released a statement noting that as the ‘global burden of diabetes continues to rise, it is more important than ever to protect and strengthen the foundations of scientific research.’ The statement follows an incident in which five researchers were escorted out of the American Diabetes Association annual meeting by police.

Chemicals in Breast Milk

Endocrine-disrupting chemicals were found in breast milk and in the urine of infants up to 6 months old, according to new research presented at ENDO 2026. Catch up on more research from the meeting here.

A provision in the defense policy bill to expand coverage of fertility services for military members was scrapped. (The Hill)

Women with primary infertility had an increased risk of early menopause and collectively underwent menopause 1 year earlier compared with women without a history of primary infertility, a retrospective cohort study indicated. (Menopause)

Acromegaly Treatment Update

The FDA once again rejected Camurus’ octreotide extended-release injection for the treatment of acromegaly, citing lingering manufacturing and labeling issues.

UnitedHealth Group has tentatively settled with the Federal Trade Commission, becoming the last of the top three pharmacy benefit managers to resolve allegations of inflating insulin costs. (Healthcare Dive)

A federal judge blocked the Trump administration from accessing California hospital records for transgender minors. (Advocate)

The normalization of late-night salivary cortisol was tied to improved psychological well-being in patients with biochemically controlled Cushing syndrome, a cross-sectional study found. (Journal of Clinical Endocrinology & Metabolism)

Nota de descargo de responsabilidad: Esta información es solo para fines informativos y no debe ser considerada como un consejo médico. Siempre consulte a un profesional de la salud para obtener asesoramiento sobre su salud y tratamientos.

Fuente: https://www.medpagetoday.com/endocrinology/generalendocrinology/121784